Uptake of Maintenance Immunotherapy and Changes in Upstream Treatment Selection Among Patients With Urothelial Cancer

This cohort study compares the proportion of patients with urothelual cancer who initiated first-line chemotherapy and immune checkpoint inhibitors during the periods before and after avelumab approval.

Detalles Bibliográficos
Autores principales: Mamtani, Ronac, Zhang, Hanxi, Parikh, Ravi B., Patel, Khilna, Li, Haojie, Imai, Kentaro, Hubbard, Rebecca A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105303/
https://www.ncbi.nlm.nih.gov/pubmed/37058309
http://dx.doi.org/10.1001/jamanetworkopen.2023.8395
Descripción
Sumario:This cohort study compares the proportion of patients with urothelual cancer who initiated first-line chemotherapy and immune checkpoint inhibitors during the periods before and after avelumab approval.

Ejemplares similares